SurModics (SRDX) Reports Q1 EPS of $0.12, Revenues Beat; Raises FY19 EPS/Revenue Mid-Point Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to SurModics (SRDX) Reports Q1 EPS of $0.12, Revenues Beat; Raises FY19 EPS/Revenue Mid-Point Guidance Above Consensus

Surmodics Reports First Quarter Fiscal 2019 Results

January 30, 2019 4:05 PM EST

Updates Fiscal 2019 Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 first quarter ended December 31, 2018 and updated its financial outlook for fiscal 2019.

Summary of First Quarter Fiscal 2019 Highlights

Revenue of $22.2 million, an increase of 31% year-over-year GAAP EPS of $0.09, non-GAAP EPS of $0.12 Updating fiscal 2019 revenue and EPS guidance Initial patient... More